Pfizer says it will end global development of gene therapy Beqvez, Nikkei reports
ReutersFeb 20, 2025 7:58 PM
Feb 20 (Reuters) - Pfizer PFE.N will end global development of its bleeding disorder gene therapy, Beqvez, the Nikkei reported on Thursday.
Beqvez was approved in the U.S. last year, for the treatment of adults with moderate to severe hemophilia B.
Disclaimer: For information purposes only. Past performance is not indicative of future results.
Related Articles
Rivian Reaches Key Milestones, Yet Faces Headwinds Ahead
TradingKey - Rivian has announced an important milestone in february 20, reporting its first-ever "positive gross profit" for the fourth quarter of 2024.TradingKey
8 hours ago
Walmart Stock Drops 6% After Q4 FY2025 Earnings: 5 Key Takeaways for Investors
TradingKey - The US consumer has remained strong over the past few years, despite higher inflation and higher interest rates. That may have surprised some market watchers but certain listed companies have cashed in on this strength in the US consumer.TradingKey
11 hours ago
Walmart Q4 Earnings: The Growth of Retail Sales Might Shrink, Watched Out Valuation Risks
From the perspective of the overall retail industry, although the announced holiday consumption growth rate at the end of 2024 was 3.8%, higher than 3.1% in 2023, the actual overall retail industry consumption trend is showing a phased deceleration.TradingKey
11 hours ago
